Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis
NCT ID: NCT01885429
Last Updated: 2013-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2011-01-31
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Leucine in the Regulation of Human Myofibrillar Protein Synthesis at Rest and Following Resistance Exercise
NCT01492010
Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults
NCT02371278
Supplementation of a Leucine-enriched Protein Blend
NCT03796897
Effects of Essential and Non-Essential Amino Acids on Post-Exercise Muscle Collagen Synthesis in Young Men
NCT04596553
Effect of Amino Acid on Muscle Damage
NCT03319147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Positive Control
Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
Positive Control
Subject consumes 25g of whey protein following unilateral exercise
Negative Control
Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
Negative Control
Subject consumes 6.25g of whey protein following unilateral exercise
Low Protein + Low Leucine Spike
Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
Low Protein Low Leucine Spike
Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
Low Protein + High Leucine Spike
Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
Low Protein High Leucine Spike
Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
Low Protein + High Leucine + BCAA Spike
Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
Low Protein + High Leucine + BCAA Spike
Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Positive Control
Subject consumes 25g of whey protein following unilateral exercise
Negative Control
Subject consumes 6.25g of whey protein following unilateral exercise
Low Protein Low Leucine Spike
Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
Low Protein High Leucine Spike
Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
Low Protein + High Leucine + BCAA Spike
Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy and physically active (as determined by medical and activity questionnaire)
* 18-35 years of age
* 70-90 kg body mass
* Having given informed consent
Exclusion Criteria
* Having any identified metabolic or intestinal disorders
* Tobacco use
* Aspirin use in the 4 days prior to the experimental trial
* Consumption of prescription medications or any performance enhancing agent
* Inability to endure the strenuous exercise bouts e.g. injuries
* Alcohol intake during the 48 hours prior to each of the testing days
* Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study
* Have given blood in the last three weeks
* Verbal confirmation that they have used a substance on the WADA banned list within the last year
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stuart M Phillips, PhD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
McMaster University
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10.32.NRC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.